

19



Europäisches Patentamt
European Patent Office
Office européen des brevets



11 Publication number:

0 290 496 B1

12

EUROPEAN PATENT SPECIFICATION

45 Date of publication of patent specification: **28.10.92** 51 Int. Cl.⁵: **A61K 31/70**, A61K 49/00,
A61K 31/52

21 Application number: **87906894.8**

22 Date of filing: **05.10.87**

86 International application number:
PCT/US87/02524

87 International publication number:
WO 88/02258 (07.04.88 88/08)

54 **USE OF AN ADENOSINE, HYPOXANTHINE AND RIBOSE-CONTAINING SOLUTION FOR IMPROVED PROTECTION OF THE HEART DURING SURGERY.**

30 Priority: **06.10.86 US 915557**

43 Date of publication of application:
17.11.88 Bulletin 88/46

45 Publication of the grant of the patent:
28.10.92 Bulletin 92/44

84 Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

73 Proprietor: **THE UNIVERSITY OF VIRGINIA
ALUMNI PATENTS FOUNDATION
Towers Office Building, Suite 6-211, 1224
West Main Street
Charlottesville, Virginia 22903(US)**

72 Inventor: **MENTZER, Robert, M., Jr.
Dept. of Surgery U.Va. Medical Center
Charlottesville, VA 22908(US)
Inventor: ELY, Stephen, W.
Route 1 Box 55
Troy, VA 22974(US)
Inventor: BERNE, Robert, M.
Dept. of Physiology U.Va. Medical Center
Charlottesville, VA 22908(US)
Inventor: LASLEY, Robert, D.
Dept. of Physiology U.Va. Medical Center
Charlottesville, VA 22908(US)**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

(56) References cited:

EP-A- 0 085 033	EP-A- 0 152 148
US-A- 2 994 640	US-A- 3 868 451
US-A- 3 914 414	US-A- 3 992 531
US-A- 4 299 832	US-A- 4 338 319
US-A- 4 360 522	US-A- 4 388 308
US-A- 4 415 556	US-A- 4 473 571
US-A- 4 481 197	US-A- 4 501 735
US-A- 4 514 405	US-A- 4 544 556
US-A- 4 546 095	US-A- 4 590 180
US-A- 4 593 019	US-A- 4 605 644
US-A- 4 614 732	US-A- 4 673 563
US-A- 4 693 996	

CHEST, vol. 83, no. 5, May 1983;
N.A.SILVERMAN et al., pp. 787-792*

J. THORAC. CARDIOVASC. SURG., vol. 84, no.
1, July 1982; S.M.HUMPHREY et al.*

DIALOG INFORMATION SERVICES, File 155,
Medline 66-89; F.Z.MEERSON et al., no.
1368107*

DIALOG INFORMATION SERVICES, File 155,
Medline 66-89; E.E.BELEN KII et al., no.
891392*

SCAND. J. THORAC. CARDIOVASC. SURG.,
vol. 20, no. 3, 1986; T.HIRAYAMA et al., pp.
247-252*

J. THORAC. CARDIOVASC. SURG., vol. 90, no.
1, July 1985; J.R.STEWART et al., pp. 68-72*

J. THORAC. CARDIOVASC. SURG., vol. 97, no.
5, May 1989; D.A.WYATT et al., pp. 771-778*

J. MOL. CELL CARDIOL., vol. 20, no. 3, March
1988; S.TAKEO et al., pp. 187-199*

(74) Representative: **Stebbing, Peter John Hunter**
et al
F.J. CLEVELAND & COMPANY 40-43, Chan-
cery Lane
London WC2A 1JO(GB)

Description

Background of the Invention

5 The present invention relates to an improved cardioplegic solution to protect the heart from ischemia-induced damage incurred during interruption of the blood circulation to the heart during surgery and transplantation.

Surgical procedures for the correction of complex congenital heart abnormalities, placement of cardiac valvular prostheses or repair of defective valves, and bypassing obstructed coronary vessels require the
10 body to be supported by the heart-lung machine while the heart is rendered quiescent by interruption of its blood supply and briefly perfusing it with a cold solution containing electrolytes and a high potassium concentration (cardioplegic solution). This enables the surgeon to work in a still and bloodless field to complete the intricate surgical procedures before irreversible ischemic damage is incurred.

The ischemic heart tolerates ischemia for 20-30 minutes before irreversible damage occurs. With the
15 onset of ischemia, the supply of substrates for energy production ceases, and the high energy phosphate adenosine triphosphate (ATP) (which provides energy for contraction and operation of ion pumps in the myocardial cell) is degraded over time to its precursors ADP and AMP. AMP can undergo further degradation at the myocardial membrane to the diffusable purine nucleoside adenosine. Adenosine is also rapidly metabolized to inosine, hypoxanthine and xanthine. With the restoration of blood flow, these
20 nucleosides are washed out of the heart via the circulation. If the ischemia time has been of sufficient length, the level of ATP is reduced, hence less energy for contraction and maintenance of ionic fluxes, and the contractile function of the heart may be diminished or lost. Therefore, methods were developed which would extend the length of time the heart could tolerate ischemia in order to reduce the morbidity and mortality of cardiac operations. Investigations of possible solutions useful in delaying the onset of ischemic
25 damage have involved the use of a multitude of ingredients, but the standard cardioplegic solution in use today contains normal plasma concentrations of electrolytes with the exception of an elevated concentration of potassium which depolarizes the cardiac muscle, rendering it quiescent. The use of hyperkalemic solutions with hypothermia to lower the basal metabolic rate of the cardiac tissue reduces the rate of ATP degradation during ischemia and increases the tolerated ischemic time of the heart during surgery. The
30 protection afforded by these techniques, however, is not optimal in all cases and inadequate myocardial protection during prolonged ischemia is responsible for prolonged weaning from the cardiopulmonary bypass machine, the use of inotropic drugs to support the failing heart postoperatively, and for the mortality associated with postoperative arrhythmias or cardiac failure. Therefore, improvements in the protective cardioplegic solution are needed to reduce the risks attendant with cardiac surgical procedures.

35 J. Thorac. Cardiovasc. Surg. Vol 84, p.16 to 22 1982 shows the metabolic links between adenosine and hypoxanthine. Medline Abstract No 00891392; Farmakol, Toksikol (USSR) 1968, Vol 31, P 273-277 indicates that purines such as hypoxanthine and adenine have positive effects on the heart; while US-A-4,605,644 discloses the use of adenine and ribose for the perfusion of cardiac tissue, and J. Thorac. Cardiovasc. Surg. Vol 90, P68-72 1985 discloses the use of allopurinol for the prevention of perfusion injury.


40 We have discovered that the measured ability of the myocardium to tolerate ischemia can be enhanced significantly with the addition of adenosine, hypoxanthine and ribose to standard electrolyte solutions.

According to the present invention, therefore, there is provided the use of the compounds adenosine, hypoxanthine and ribose as additives to a heart perfusate in the manufacture of a cardioplegic solution for
45 reducing ischemic damage to a heart isolated from a normal blood supply.

The improved effect can be measured in terms of greater preservation of high energy phosphates during ischemia, more rapid recovery of high energy phosphates after ischemia, and a greater recovery of contractile function following an ischemic period. The use of this solution provides increased protection of the heart during ischemia incurred during surgery, or during the transportation of the heart between donor and recipient for cardiac transplantation.

50 Adenosine, hypoxanthine and ribose are endogenous substances. Adenosine is a purine nucleoside; hypoxanthine is a purine base; ribose is a sugar. When these substances are used as additives to standard cardioplegic solutions, a relatively high local concentration in the heart can be achieved, without exposure to the systemic circulation. Since these substances are washed out of the myocardium and rapidly distributed and metabolized, they provide a very wide margin of safety.

55 The rationale behind the use of these substances is to facilitate the preservation and repletion of the adenine nucleotide pool during ischemia by serving as substrate for the purine nucleotide salvage pathways. These pathways are summarized below.



During ischemia, the intracellular adenine nucleotide pool is degraded to the diffusible nucleosides adenosine, inosine and hypoxanthine. These are then washed out during the reperfusion period. ATP levels may be depressed for as long as 7-10 days due to the loss of these nucleotide precursors adenosine, inosine, hypoxanthine. The restoration of the adenine nucleotides can be accomplished via two major pathways. The first is via de novo synthesis; however, this pathway is very slow and more than one week would be required to replenish a 50% decline in ATP levels. The second mechanism includes the nucleotide salvage pathways which include the direct phosphorylation of adenosine to AMP, and the phosphorylation of hypoxanthine to IMP which is then converted to AMP. From AMP, ADP and ultimately ATP can be regenerated if irreversible damage of the intracellular organelles has not occurred. The salvaged hypoxanthine requires its condensation with phosphoribosyl-pyrophosphate (PRPP) which in turn is derived from the ribose moiety. Thus, in the absence of damage to the cells' biochemical machinery, the cell is capable of regenerating these high energy phosphate pools (AMP, ADP, ATP) relatively rapidly. Yet in actuality, the restoration of high energy phosphates post-ischemia occurs quite slowly. The retarded rate of recovery may be due to the low concentrations of substrate precursor in the form of adenosine, hypoxanthine and ribose.

The discovery that adenosine and hypoxanthine are individually capable of preserving and/or restoring myocardial ATP was achieved in experiments carried out in the Langendorff isolated perfused rat heart model. Adenosine (100 μ M) or hypoxanthine (100 μ M) were used in addition to a standard heart perfusate, and the effects on preischemic, ischemic and post-ischemic ATP values were determined and are presented in Table 1 by way of comparison.

TABLE 1

ATP μ moles/g wet weight					
	Equilibration	10' Ischemia	15' RP	30' RP	60' RP
Untreated	3.4 $\pm$ 0.1	1.2 $\pm$ 0.1	2.1 $\pm$ 0.7	2.1 $\pm$ 0.1	2.1 $\pm$ 0.1
Adenosine	3.9 $\pm$ 0.4	1.7 $\pm$ 0.1	2.9 $\pm$ 0.8	2.7 $\pm$.08	2.7 $\pm$.06
Untreated	3.4 $\pm$.1	1.4 $\pm$.1	2.3 $\pm$.1	2.2 $\pm$.1	1.8 $\pm$.2
Hypoxanthine	3.4 $\pm$.2	1.4 $\pm$.2	2.7 $\pm$.2	2.7 $\pm$.1	2.3 $\pm$.1
RP = reperfusion, N $\geq$ 5, T = 37°C					

These experiments demonstrated that adenosine or hypoxanthine are able to enhance nucleotide pools (ATP) during ischemia and/or during the post-ischemic reperfusion period. The improvement on energy stores would theoretically improve the functional recovery of the heart since ATP is necessary for contractile activity. This hypothesis was also tested using the aforementioned isolated rat heart model. The effects of adenosine and hypoxanthine on the recovery of cardiac contractile function was assessed by the determination of left ventricular developed pressure during the post ischemic reperfusion phase with the use of an intra-ventricular saline filled balloon. These results are shown in Table 2 by way of comparison

TABLE 2

% of Control Developed Pressure				
	Control	15' RP	30' RP	60' RP
Untreated	100%	75±7	73±6	73±6
Adenosine	100%	86±3	96±3	95±3
Untreated	100%	76±5	74±5	82±5
Hypoxanthine	100%	84±5	88±2	87±3
RP = Reperfusion, N ≥ 5, T = 37°C				

These data established that either adenosine or hypoxanthine is capable of restoring the contractile function of the isolated perfused rat heart after a period of 10 minutes of total ischemia.

To extend these studies from an *in vitro* system to a clinically relevant *in vivo* model, we compared the effects of a standard cardioplegic electrolyte solution versus the same electrolyte solution with the exception of the addition of adenosine, hypoxanthine and ribose. Using dogs on cardiopulmonary bypass, the same protocol was used as is conventional in clinical cardiac surgery. The animals were anesthetized, placed on the cardiopulmonary bypass machine and a saline-filled balloon was inserted into the left ventricle of the heart to record developed pressure. Following stabilization of hemodynamic variables, the hearts were flushed via the native coronary circulation with either a standard cardioplegic solution or the same solution containing adenosine, hypoxanthine and ribose for five minutes prior to the onset of ischemia. The electrolyte contents of these two solutions are shown in Table 3.

TABLE 3

	Standard Cardioplegic Solution	Invented Cardioplegic Solution
Na	110 meq/l	110 meq/l
Cl	160 meq/l	160 meq/l
K	16 meq/l	16 meq/l
Ca + +	2.4 meq/l	2.4 meq/l
Mg	32 meq/l	32 meq/l
Ado	0	100 μmoles/l
Hx	0	100 μmoles/l
Ribose	0	2 mmoles/l

The pH of each solution was adjusted to 7.4 and the osmolarity was approximately 300 mosm in each. Following cardioplegic arrest, the heart was made ischemic for 1 hour at 37 ° C. During the hour of ischemia, serial biopsies were obtained to determine the rate of ATP degradation in the untreated and treated group. These results are shown in Table 4.

TABLE 4

APT (μ moles/gm wet weight)					
	30' equilibration	15' ischemia	30' ischemia	45' ischemia	60' ischemia
Untreated (Std cardioplegia)	5.09±.24	3.67±.24	3.01±.25	2.03±.30	1.97±.13
Treated Std cardioplegia + Adenosine, Hypoxanthine, Ribose)	5.29±.20	4.51±.42	4.03±.42	3.07±.48	2.74±.27
N ≥ 5 in each group					

These data show that our invented cardioplegia solution reduces the rate of ATP degradation during ischemia. This finding applies to hearts undergoing conventional cardiac surgical protocols and hearts harvested for cardiac transplantation.

During the post-ischemic reperfusion period, the recovery of ATP pools and the recovery of left heart contractile function were also assessed in the dog model described above. The effects of ischemia on the heart protected with the standard cardioplegic solution were compared to the hearts protected with the same solution except for the addition of adenosine, hypoxanthine and ribose. These results, expressed in terms of recovery of ATP and left heart function, are shown in Table 5.

TABLE 5

ATP

 $\mu\text{moles/gr wet weight}$

	15' RP	30' RP	60' RP
Untreated (Std. solution)	2.77 $\pm$.22	2.13 $\pm$.21	2.95 $\pm$.16
Treated (Std solution + Adenosine, Hypoxanthine, Ribose)	3.24 $\pm$.39	3.22 $\pm$.32	3.33 $\pm$.33

% Recovery of Developed Pressure

	15' RP	30' RP	45' RP	60' RP
Untreated (Std. solution)	19 $\pm$ 3.0	27 $\pm$ 3.2	42 $\pm$ 1	49 $\pm$ 3
Treated (Std solution + Adenosine, Hypoxanthine, Ribose)	25 $\pm$ 4	40 $\pm$ 4	54 $\pm$ 3	67 $\pm$ 4

N $\geq$ 5

These experiments shown that the protection of the heart during one hour of ischemia at 37° C is greater in terms of preservation and recovery of ATP levels and in terms of recovery of the contractile function of the heart when the invented solution containing adenosine, hypoxanthine and ribose is compared to a standard clinically accepted cardioplegic solution.

Preferably, the invention is embodied in:

- (1) A formula for preparation of a solution for reducing ischemic damage to the heart during cardiac surgery or during harvesting for cardiac transplantation. This solution has the following ionic content:

Na	110 meq/l
Cl	160 meq/l
K	16 meq/l
Ca + +	1.4 meq/l
Mg	32 meq.
Adenosine in quantity to yield a final conc. of 100 μ moles/l	
Hypoxanthine in quantity to yield a final conc. of 100 μ moles/l	
Ribose in quantity to yield a final conc. of 2 mmoles/l	
+ NaHCO ₃ or HCl to adjust pH to 7.4	

The above solution represents an improvement over a standard cardioplegic solution due to the addition of adenosine, hypoxanthine and ribose.

(2) A method for reducing ischemic damage to the heart during operations or transplantation by the use of the above invented solution as an infusion to arrest the heart prior to ischemia during operations or prior to harvesting hearts from donors in preparation for transplantations.

Claims

1. The use of the compounds adenosine, hypoxanthine and ribose as additives to a heart perfusate in the manufacture of a cardioplegic solution for reducing ischemic damage to a heart isolated from a normal blood supply.
2. The use according to claim 1 wherein the final concentrations of adenosine and hypoxanthine respectively in the solution are 100 μ moles per litre.
3. The use according to claim 1 wherein the ribose additive has a final concentration in the solution of 2 mmoles.
4. The use according to claims 2 and 3 wherein the additive further comprises Na, Cl, K, Ca and Mg ions in solution.
5. The use according to claim 4 wherein the ions in solution have the following concentrations:

Na	110 meq/l
Cl	160 meq/l
K	16 meq/l
Ca + +	2.4 meq/l
Mg	32 meq, and
NaHCO ₃ or HCl to adjust pH to 7.4.	

6. A method for reducing ischemic damage to the heart when isolated from the functioning body which comprises perfusing the heart with a cardioplegic solution as claimed in any one of claims 1 to 5.

Patentansprüche

1. Verwendung von Adenosin, Hypoxanthin und Ribose als Zusatzbestandteile zu einem Herzperfusat bei der Herstellung einer kardioplegischen Lösung zur Verminderung ischämischer Schädigung eines von der üblichen Blutversorgung abgetrennten Herzens.
2. Verwendung nach Anspruch 1, wobei die endgültige Konzentration von Adenosin bzw. Hypoxanthin in der Lösung 100 μ Mol je Liter beträgt.
3. Verwendung nach Anspruch 1, wobei das hingefügte Ribose eine endgültige Konzentration in der Lösung 2 m-Mol beträgt.

4. Verwendung nach Anspruch 2 und 3, wobei Na-, Cl-, N-, Ca- und Mg-Ionen weitere Zusatzbestandteile in der Lösung sind.

5. Verwendung nach Anspruch 4, wobei die Ionen in der Lösung in folgender Konzentration vorhanden sind:

Na	110 meq/l
Cl	160 meq/l
K	16 meq/l
Ca + +	2.4 meq/l
Mg	32 meq und
NaHCO ₃ oder HCl zur Einstellung des pH-Wertes auf 7,4.	

6. Verfahren zur Verringerung von ischämischer Schädigung des Herzens, nach dessen Isolation von einem funktionstüchtigen Körper, indem dieser mit einer kardioplegischen Lösung nach einem beliebigen der Ansprüche 1 bis 5 versorgt wird.

Revendications

1. Utilisation des composés adénosine, hypoxanthine et ribose, en tant qu'additifs à un perfusé du coeur dans la fabrication d'une solution cardioplégique, pour réduire la dégradation ischémique d'un coeur isolé d'une alimentation en sang normale.

2. Utilisation selon la revendication 1, où les concentrations finales d'adénosine et d'hypoxanthine, respectivement, dans la solution, sont de 100 μ moles par litre.

3. Utilisation selon la revendication 1, où le ribose additif a une concentration finale dans la solution de 2 mmoles.

4. Utilisation selon les revendications 2 et 3, où l'additif contient de plus les ions Na, Cl, K, Ca et Mg en solution.

5. Utilisation selon la revendication 4, où les ions en solution ont les concentrations suivantes :

Na	110 meq/l
Cl	160 meq/l
K	16 meq/l
Ca + +	2,4 meq/l
Mg	32 meq, et
NaHCO ₃ ou HCl pour ajuster pH à 7,4.	

6. Méthode de réduction de la dégradation ischémique du coeur, lorsqu'il est isolé du corps en fonctionnement, qui comprend la perfusion du coeur par une solution cardioplégique, selon l'une quelconque des revendications 1 à 5.